| Followers | 42 |
| Posts | 4316 |
| Boards Moderated | 0 |
| Alias Born | 07/14/2010 |
Thursday, May 12, 2022 10:41:27 AM
Double debt
Profitability
Profit Margin-6.89%
MNGT Effectiveness
Return on Equity -7.15%
Balance Sheet - Double debt
Total Cash 105.36M
Total Cash Per Share $1.53
Total Debt 190.07M
Profitability
Profit Margin-6.89%
MNGT Effectiveness
Return on Equity -7.15%
Balance Sheet - Double debt
Total Cash 105.36M
Total Cash Per Share $1.53
Total Debt 190.07M
Recent LNTH News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 11:44:51 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 11:36:50 AM
- Lantheus Reports First Quarter 2026 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/07/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/01/2026 08:30:57 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 03:00:43 PM
- Lantheus to Host First Quarter 2026 Earnings Conference Call and Webcast on May 7, 2026, at 8:00 a.m. Eastern Time • GlobeNewswire Inc. • 04/23/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 08:44:50 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/20/2026 08:16:35 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/20/2026 08:13:32 PM
- Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs) • GlobeNewswire Inc. • 03/17/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 09:06:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 09:05:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 09:05:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 09:05:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 09:05:00 PM
- Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection • GlobeNewswire Inc. • 03/06/2026 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 09:19:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 09:19:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 09:19:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 09:18:58 PM
- Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA® • GlobeNewswire Inc. • 03/02/2026 01:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:38:33 PM
- Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/26/2026 12:00:00 PM
